Latest Health News

CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.

NexGen Energy is advancing through the final Canadian Nuclear Safety Commission hearing for its Rook I uranium project, buoyed by strong Indigenous community support and over a decade of environmental and social groundwork.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

StepChange Holdings has reported robust organic growth with a 19% revenue increase in its first half as an ASX-listed company, complemented by a strategic acquisition expanding its government sector presence.

Eden Innovations has appointed Dr Allan Godsk Larsen as Managing Director to spearhead its global growth, leveraging his deep expertise in carbon nanotube technology amid strong commercial momentum and significant debt reduction.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Future Generation Global Limited has announced a substantial 49% increase in its fully franked dividend for FY2025, alongside a special dividend, reflecting robust portfolio performance and a commitment to shareholder returns.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.